 |
|
|
| |
High Efficacy of Treatment With Sofosbuvir + GS-5816 ± Ribavirin for 12 Weeks in Treatment-Experienced Patients With Genotype 1 or 3 HCV Infection
|
| |
| |
Reported by Jules Levin
AASLD 2014 Boston Nov 7-11
Stephen Pianko1, Steven L. Flamm2, Mitchell L. Shiffman3, Sonal Kumar4, Simone Strasser5, Gregory J. Dore 6, John McNally7, Diana M. Brainard7, Lingling Han7, Brian Doehle7, Erik Mogalian7, John G. McHutchison7, K. Rajender Reddy 8, Stuart K. Roberts 9
1Monash Medical Centre, Clayton, Victoria, Australia; 2Northwestern University, Chicago, IL; 3Liver Institute of Virginia, Richmond, VA; 4Weill Cornell Medical College, New York, NY; 5Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia; 6St. Vincent's Hospital, Darlinghurst, New South Wales, Australia; 7Gilead Sciences, Inc., Foster City, CA; 8University of Pennsylvania, Philadelphia, PA; 9The Alfred, Melbourne, Victoria, Australia
|
| |
|
|
|
|
|
